Xizang Haisco Pharma Invests in Regentis, an Israeli Device Maker

Xizang Haisco Pharma led a $15 million Series D funding for Regentis Biomaterials, an Israeli medical device company. As part of its investment, Haisco will own China rights to Regentis' lead product, GelrinC®, a proprietary hydrogel. Implanted as a liquid, GelrinC is cured in-situ via ultraviolet light to form a resorbable implant. Over time, the gel is gradually replaced by newly regenerated cartilage. Regentis plans to use the new capital to conduct US clinical trials of GenrinC. More details.... Stock Symbol: (SHZ: 002653) Share this with colleagues: // //